New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration

NDA FilingLAE002Positive

AI Analysis

Summary

Laekna announced that its New Drug Application for LAE002 (afuresertib) has been accepted by China's National Medical Products Administration for further review. The drug is in development for the treatment of patients with an indication not fully specified in the article excerpt.

Outcome Details

NDA accepted by China's NMPA Center for Drug Evaluation

Importance:6/10

Sentiment:

0.60

ChinaNMPANDADrug DevelopmentRegulatory

Related Companies

$NHPAP $MDCE $CHHE

Read the original article

Published by PR Newswire Biotech on August 12, 2026 12:45 AM

Read Original